Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New painkiller may replace opioids in liver cancer procedure

NCT ID NCT07034950

Symptom relief Sponsor: The First Affiliated Hospital of Xiamen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests esketamine, a drug related to ketamine, to control pain during a procedure that destroys liver tumors with heat. The goal is to find the right dose that works without needing opioids, which can cause breathing problems. 79 adults with liver cancer will receive esketamine during the procedure, and researchers will monitor their pain and breathing safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
esketamine
What this could lead to
If successful, this could provide a safer, opioid-free way to manage pain during liver tumor ablation, reducing breathing complications.
What could go wrong
This is an early-phase dose-finding study with only 79 participants. The results may not apply to all patients, and esketamine itself can cause side effects like dizziness or nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 79 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 - 80 years; * ASA physical status Ⅰ or Ⅲ; * Body mass index (BMI) 18 - 28 kg∙m-2; * Scheduled for elective ultrasound-guided thermal ablation of solitary liver tumors under HHNB. Exclusion Criteria: (i) Pharmacological contraindications: * Known hypersensitivity to study medications (esketamine, midazolam); * Opioid or benzodiazepine dependence; * Using analgesics within the last 24 h preoperatively; * Participation in other investigational drug trials within 90 days. (ii) Clinical comorbidities and surgery history: * Multifocal hepatic lesions requiring concurrent ablation; * Patients after liver transplantation; * Active upper respiratory tract infection within 14 days; * Severe cardiopulmonary diseases (New York Heart Association \[NYHA\] class Ⅲ-Ⅳ, FEV1/FVC \< 70%); * Decompensated hepatic insufficiency (Child-Pugh C); * Uncontrolled hypertension (≥180/110 mmHg), elevated intracranial/intraocular pressure, or hyperthyroidism; * Major neuropsychiatric disorders (epilepsy, schizophrenia, major depressive disorder, cognitive impairment). (iii) Procedural Risk Factors: * Anticipated difficult airway (Mallampati Ⅲ-Ⅳ, thyromental distance \< 6 cm) or anatomical airway obstruction; * Inadequate preoperative fasting (solid intake \< 8 hours, clear fluids \< 2 hours).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoma of liver and intrahepatic biliary tract liver and intrahepatic bile duct neoplasm liver cancer Liver Neoplasms Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatic cancer Hepatic neoplasm

Contacts and locations

Locations

  • Department of Anesthesiology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, China

    Xiamen, Fujian, 361000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.